Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors
•Patient characteristics were associated with treatment patterns in HCC.•Tislelizumab, camrelizumab, and tislelizumab + TACE had similar effectiveness in advanced HCC.•PVTT was an independent risk factor for PFS in advanced HCC patients. Programmed cell death protein-1 (PD-1) inhibitors have shown p...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2024-05, Vol.132, p.111947-111947, Article 111947 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 111947 |
|---|---|
| container_issue | |
| container_start_page | 111947 |
| container_title | International immunopharmacology |
| container_volume | 132 |
| creator | Zou, Huimin Ge, Ying Chen, Wenge Yao, Dongning Oi Lam Ung, Carolina Lai, Yunfeng Hu, Hao |
| description | •Patient characteristics were associated with treatment patterns in HCC.•Tislelizumab, camrelizumab, and tislelizumab + TACE had similar effectiveness in advanced HCC.•PVTT was an independent risk factor for PFS in advanced HCC patients.
Programmed cell death protein-1 (PD-1) inhibitors have shown promising clinical efficacy in treating advanced hepatocellular carcinoma (HCC). However, little evidence exists regarding their treatment patterns and outcomes in real-world practice in China. This study aimed to investigate real-world treatment patterns and outcomes of PD-1 inhibitors as first-line therapies for patients with advanced HCC in China.
The study population included adult patients with advanced HCC who were initially treated with PD-1 inhibitors from April 2020 to November 2022 in China. Descriptive statistics were used to report first-line treatment patterns and associations between patient characteristics and the most frequently used treatment patterns. The effectiveness of first-line treatment with PD-1 inhibitors was also evaluated according to survival and tumor response.
The analyses enrolled 480 patients. The four most frequently used first-line treatment patterns of camrelizumab, tislelizumab, camrelizumab + TACE, and tislelizumab + TACE showed statistical differences in patient characteristics of gender, HBV infection, liver cirrhosis, BCLC stage, and portal vein tumor thrombus (all P |
| doi_str_mv | 10.1016/j.intimp.2024.111947 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3022570196</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S156757692400465X</els_id><sourcerecordid>3022570196</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-21168798744bced31d593920fc5d4e0da6325a5e12aafe03524306557594737c3</originalsourceid><addsrcrecordid>eNp9UU1v3CAURFWrfDX_oKo49uIND4yxL5WqfEuRGlXtGbHwrGVlmy3gRPkB-d9h47THnEDMzBveDCFfgK2AQXO2Xfkp-3G34ozXKwDoavWBHEGr2goUkx_LXTaqkqrpDslxSlvGynsNB-RQtFJy3jVH5PkXmqF6DHFwNEc0ecQp053JGeOUqJkcDXO2YcRE-xD3iC-MRB993lDjHsxk0dENFiBYHIZ5MJFaE62fwmion3z2ZhielumF-iq8v6igYBu_9jnE9Jl86s2Q8PTtPCF_ri5_n99Udz-vb89_3FVWAOSKAzSt6lpV1-viKsDJTnSc9Va6GpkzjeDSSARuTI9MSF4L1kipZMlGKCtOyLdl7i6GvzOmrEef9r82E4Y5acE4l4pB1xRqvVBtDClF7PUu-tHEJw1M7wvQW70UoPcF6KWAIvv65jCvR3T_Rf8SL4TvCwHLng8eo062JFrW8RFt1i749x1eAJaXmrk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3022570196</pqid></control><display><type>article</type><title>Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Zou, Huimin ; Ge, Ying ; Chen, Wenge ; Yao, Dongning ; Oi Lam Ung, Carolina ; Lai, Yunfeng ; Hu, Hao</creator><creatorcontrib>Zou, Huimin ; Ge, Ying ; Chen, Wenge ; Yao, Dongning ; Oi Lam Ung, Carolina ; Lai, Yunfeng ; Hu, Hao</creatorcontrib><description>•Patient characteristics were associated with treatment patterns in HCC.•Tislelizumab, camrelizumab, and tislelizumab + TACE had similar effectiveness in advanced HCC.•PVTT was an independent risk factor for PFS in advanced HCC patients.
Programmed cell death protein-1 (PD-1) inhibitors have shown promising clinical efficacy in treating advanced hepatocellular carcinoma (HCC). However, little evidence exists regarding their treatment patterns and outcomes in real-world practice in China. This study aimed to investigate real-world treatment patterns and outcomes of PD-1 inhibitors as first-line therapies for patients with advanced HCC in China.
The study population included adult patients with advanced HCC who were initially treated with PD-1 inhibitors from April 2020 to November 2022 in China. Descriptive statistics were used to report first-line treatment patterns and associations between patient characteristics and the most frequently used treatment patterns. The effectiveness of first-line treatment with PD-1 inhibitors was also evaluated according to survival and tumor response.
The analyses enrolled 480 patients. The four most frequently used first-line treatment patterns of camrelizumab, tislelizumab, camrelizumab + TACE, and tislelizumab + TACE showed statistical differences in patient characteristics of gender, HBV infection, liver cirrhosis, BCLC stage, and portal vein tumor thrombus (all P < 0.05). However, there was no significant difference in median progression-free survival among the first-line treatments of tislelizumab, camrelizumab, and tislelizumab + TACE (not reached vs. 4.4 months vs. 3.6 months, P = 0.5178). The three groups had similar objective response rates (25.0 % vs. 28.6 % vs. 28.6 %, P = 0.927), and disease control rates (73.1 % vs. 78.6 % vs. 64.3 %, P = 0.573) with no statistical significance.
Our findings provided insights into potential therapeutic strategies of PD-1 inhibitors in first-line settings for advanced HCC in real-world practice in China. It was recommended to consider patient characteristics associated with therapeutic options when making clinical decisions. Prospective randomized controlled studies with larger sample sizes and longer follow-up times were warranted further to verify the potential clinical benefits of PD-1 inhibitors.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2024.111947</identifier><identifier>PMID: 38552296</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal, Humanized - therapeutic use ; Camrelizumab ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - mortality ; Chemoembolization, Therapeutic ; China ; Female ; Hepatocellular carcinoma ; Humans ; Immune Checkpoint Inhibitors - therapeutic use ; Liver Neoplasms - drug therapy ; Liver Neoplasms - mortality ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed cell death protein-1 inhibitor ; Retrospective Studies ; Tislelizumab ; Treatment Outcome</subject><ispartof>International immunopharmacology, 2024-05, Vol.132, p.111947-111947, Article 111947</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c311t-21168798744bced31d593920fc5d4e0da6325a5e12aafe03524306557594737c3</cites><orcidid>0000-0001-9441-106X ; 0000-0002-6239-3335</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2024.111947$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38552296$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zou, Huimin</creatorcontrib><creatorcontrib>Ge, Ying</creatorcontrib><creatorcontrib>Chen, Wenge</creatorcontrib><creatorcontrib>Yao, Dongning</creatorcontrib><creatorcontrib>Oi Lam Ung, Carolina</creatorcontrib><creatorcontrib>Lai, Yunfeng</creatorcontrib><creatorcontrib>Hu, Hao</creatorcontrib><title>Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•Patient characteristics were associated with treatment patterns in HCC.•Tislelizumab, camrelizumab, and tislelizumab + TACE had similar effectiveness in advanced HCC.•PVTT was an independent risk factor for PFS in advanced HCC patients.
Programmed cell death protein-1 (PD-1) inhibitors have shown promising clinical efficacy in treating advanced hepatocellular carcinoma (HCC). However, little evidence exists regarding their treatment patterns and outcomes in real-world practice in China. This study aimed to investigate real-world treatment patterns and outcomes of PD-1 inhibitors as first-line therapies for patients with advanced HCC in China.
The study population included adult patients with advanced HCC who were initially treated with PD-1 inhibitors from April 2020 to November 2022 in China. Descriptive statistics were used to report first-line treatment patterns and associations between patient characteristics and the most frequently used treatment patterns. The effectiveness of first-line treatment with PD-1 inhibitors was also evaluated according to survival and tumor response.
The analyses enrolled 480 patients. The four most frequently used first-line treatment patterns of camrelizumab, tislelizumab, camrelizumab + TACE, and tislelizumab + TACE showed statistical differences in patient characteristics of gender, HBV infection, liver cirrhosis, BCLC stage, and portal vein tumor thrombus (all P < 0.05). However, there was no significant difference in median progression-free survival among the first-line treatments of tislelizumab, camrelizumab, and tislelizumab + TACE (not reached vs. 4.4 months vs. 3.6 months, P = 0.5178). The three groups had similar objective response rates (25.0 % vs. 28.6 % vs. 28.6 %, P = 0.927), and disease control rates (73.1 % vs. 78.6 % vs. 64.3 %, P = 0.573) with no statistical significance.
Our findings provided insights into potential therapeutic strategies of PD-1 inhibitors in first-line settings for advanced HCC in real-world practice in China. It was recommended to consider patient characteristics associated with therapeutic options when making clinical decisions. Prospective randomized controlled studies with larger sample sizes and longer follow-up times were warranted further to verify the potential clinical benefits of PD-1 inhibitors.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Camrelizumab</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Chemoembolization, Therapeutic</subject><subject>China</subject><subject>Female</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Programmed cell death protein-1 inhibitor</subject><subject>Retrospective Studies</subject><subject>Tislelizumab</subject><subject>Treatment Outcome</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v3CAURFWrfDX_oKo49uIND4yxL5WqfEuRGlXtGbHwrGVlmy3gRPkB-d9h47THnEDMzBveDCFfgK2AQXO2Xfkp-3G34ozXKwDoavWBHEGr2goUkx_LXTaqkqrpDslxSlvGynsNB-RQtFJy3jVH5PkXmqF6DHFwNEc0ecQp053JGeOUqJkcDXO2YcRE-xD3iC-MRB993lDjHsxk0dENFiBYHIZ5MJFaE62fwmion3z2ZhielumF-iq8v6igYBu_9jnE9Jl86s2Q8PTtPCF_ri5_n99Udz-vb89_3FVWAOSKAzSt6lpV1-viKsDJTnSc9Va6GpkzjeDSSARuTI9MSF4L1kipZMlGKCtOyLdl7i6GvzOmrEef9r82E4Y5acE4l4pB1xRqvVBtDClF7PUu-tHEJw1M7wvQW70UoPcF6KWAIvv65jCvR3T_Rf8SL4TvCwHLng8eo062JFrW8RFt1i749x1eAJaXmrk</recordid><startdate>20240510</startdate><enddate>20240510</enddate><creator>Zou, Huimin</creator><creator>Ge, Ying</creator><creator>Chen, Wenge</creator><creator>Yao, Dongning</creator><creator>Oi Lam Ung, Carolina</creator><creator>Lai, Yunfeng</creator><creator>Hu, Hao</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9441-106X</orcidid><orcidid>https://orcid.org/0000-0002-6239-3335</orcidid></search><sort><creationdate>20240510</creationdate><title>Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors</title><author>Zou, Huimin ; Ge, Ying ; Chen, Wenge ; Yao, Dongning ; Oi Lam Ung, Carolina ; Lai, Yunfeng ; Hu, Hao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-21168798744bced31d593920fc5d4e0da6325a5e12aafe03524306557594737c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Camrelizumab</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Chemoembolization, Therapeutic</topic><topic>China</topic><topic>Female</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Programmed cell death protein-1 inhibitor</topic><topic>Retrospective Studies</topic><topic>Tislelizumab</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zou, Huimin</creatorcontrib><creatorcontrib>Ge, Ying</creatorcontrib><creatorcontrib>Chen, Wenge</creatorcontrib><creatorcontrib>Yao, Dongning</creatorcontrib><creatorcontrib>Oi Lam Ung, Carolina</creatorcontrib><creatorcontrib>Lai, Yunfeng</creatorcontrib><creatorcontrib>Hu, Hao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zou, Huimin</au><au>Ge, Ying</au><au>Chen, Wenge</au><au>Yao, Dongning</au><au>Oi Lam Ung, Carolina</au><au>Lai, Yunfeng</au><au>Hu, Hao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2024-05-10</date><risdate>2024</risdate><volume>132</volume><spage>111947</spage><epage>111947</epage><pages>111947-111947</pages><artnum>111947</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•Patient characteristics were associated with treatment patterns in HCC.•Tislelizumab, camrelizumab, and tislelizumab + TACE had similar effectiveness in advanced HCC.•PVTT was an independent risk factor for PFS in advanced HCC patients.
Programmed cell death protein-1 (PD-1) inhibitors have shown promising clinical efficacy in treating advanced hepatocellular carcinoma (HCC). However, little evidence exists regarding their treatment patterns and outcomes in real-world practice in China. This study aimed to investigate real-world treatment patterns and outcomes of PD-1 inhibitors as first-line therapies for patients with advanced HCC in China.
The study population included adult patients with advanced HCC who were initially treated with PD-1 inhibitors from April 2020 to November 2022 in China. Descriptive statistics were used to report first-line treatment patterns and associations between patient characteristics and the most frequently used treatment patterns. The effectiveness of first-line treatment with PD-1 inhibitors was also evaluated according to survival and tumor response.
The analyses enrolled 480 patients. The four most frequently used first-line treatment patterns of camrelizumab, tislelizumab, camrelizumab + TACE, and tislelizumab + TACE showed statistical differences in patient characteristics of gender, HBV infection, liver cirrhosis, BCLC stage, and portal vein tumor thrombus (all P < 0.05). However, there was no significant difference in median progression-free survival among the first-line treatments of tislelizumab, camrelizumab, and tislelizumab + TACE (not reached vs. 4.4 months vs. 3.6 months, P = 0.5178). The three groups had similar objective response rates (25.0 % vs. 28.6 % vs. 28.6 %, P = 0.927), and disease control rates (73.1 % vs. 78.6 % vs. 64.3 %, P = 0.573) with no statistical significance.
Our findings provided insights into potential therapeutic strategies of PD-1 inhibitors in first-line settings for advanced HCC in real-world practice in China. It was recommended to consider patient characteristics associated with therapeutic options when making clinical decisions. Prospective randomized controlled studies with larger sample sizes and longer follow-up times were warranted further to verify the potential clinical benefits of PD-1 inhibitors.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38552296</pmid><doi>10.1016/j.intimp.2024.111947</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9441-106X</orcidid><orcidid>https://orcid.org/0000-0002-6239-3335</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2024-05, Vol.132, p.111947-111947, Article 111947 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3022570196 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Antibodies, Monoclonal, Humanized - therapeutic use Camrelizumab Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Chemoembolization, Therapeutic China Female Hepatocellular carcinoma Humans Immune Checkpoint Inhibitors - therapeutic use Liver Neoplasms - drug therapy Liver Neoplasms - mortality Male Middle Aged Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed cell death protein-1 inhibitor Retrospective Studies Tislelizumab Treatment Outcome |
| title | Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T23%3A43%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-world%20treatment%20patterns%20and%20outcomes%20for%20patients%20with%20advanced%20hepatocellular%20carcinoma%20initially%20treated%20with%20PD-1%20inhibitors&rft.jtitle=International%20immunopharmacology&rft.au=Zou,%20Huimin&rft.date=2024-05-10&rft.volume=132&rft.spage=111947&rft.epage=111947&rft.pages=111947-111947&rft.artnum=111947&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2024.111947&rft_dat=%3Cproquest_cross%3E3022570196%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3022570196&rft_id=info:pmid/38552296&rft_els_id=S156757692400465X&rfr_iscdi=true |